Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 May 2018
At a glance
- Drugs Damoctocog alfa pegol (Primary) ; Efmoroctocog alfa
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Bayer
- 04 May 2018 Planned End Date changed from 9 Apr 2018 to 11 Jun 2018.
- 02 Mar 2018 Planned End Date changed from 11 May 2018 to 9 Apr 2018.
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.